10 results on '"Du, Jiangxia"'
Search Results
2. Crosstalk between alveolar macrophages and alveolar epithelial cells/fibroblasts contributes to the pulmonary toxicity of gefitinib
- Author
-
Du, Jiangxia, Li, Guanqun, Jiang, Liyu, Zhang, Xiaochen, Xu, Zhifei, Yan, Hao, Zhou, Ziye, He, Qiaojun, Yang, Xiaochun, and Luo, Peihua
- Published
- 2021
- Full Text
- View/download PDF
3. s-HBEGF/SIRT1 circuit-dictated crosstalk between vascular endothelial cells and keratinocytes mediates sorafenib-induced hand–foot skin reaction that can be reversed by nicotinamide
- Author
-
Luo, Peihua, Yan, Hao, Chen, Xueqin, Zhang, Ying, Zhao, Ziying, Cao, Ji, Zhu, Yi, Du, Jiangxia, Xu, Zhifei, Zhang, Xiaochen, Zeng, Su, Yang, Bo, Ma, Shenglin, and He, Qiaojun
- Published
- 2020
- Full Text
- View/download PDF
4. Autophagic degradation of CCN2 (cellular communication network factor 2) causes cardiotoxicity of sunitinib.
- Author
-
Xu, Zhifei, Jin, Ying, Gao, Zizheng, Zeng, Yan, Du, Jiangxia, Yan, Hao, Chen, Xueqin, Ping, Li, Lin, Nengming, Yang, Bo, He, Qiaojun, and Luo, Peihua
- Subjects
SUNITINIB ,CELL death ,TELECOMMUNICATION systems ,CARDIOTOXICITY ,NEOVASCULARIZATION inhibitors ,PROTHROMBIN ,AUTOPHAGY - Abstract
Excessive macroautophagy/autophagy is one of the causes of cardiomyocyte death induced by cardiovascular diseases or cancer therapy, yet the underlying mechanism remains unknown. We and other groups previously reported that autophagy might contribute to cardiomyocyte death caused by sunitinib, a tumor angiogenesis inhibitor that is widely used in clinic, which may help to understand the mechanism of autophagy-induced cardiomyocyte death. Here, we found that sunitinib-induced autophagy leads to apoptosis of cardiomyocyte and cardiac dysfunction as the cardiomyocyte-specific Atg7
−/+ heterozygous mice are resistant to sunitinib. Sunitinib-induced maladaptive autophagy selectively degrades the cardiomyocyte survival mediator CCN2 (cellular communication network factor 2) through the TOLLIP (toll interacting protein)-mediated endosome-related pathway and cardiomyocyte-specific knockdown of Ccn2 through adeno-associated virus serotype 9 (AAV9) mimics sunitinib-induced cardiac dysfunction in vivo, suggesting that the autophagic degradation of CCN2 is one of the causes of sunitinib-induced cardiotoxicity and death of cardiomyocytes. Remarkably, deletion of Hmgb1 (high mobility group box 1) inhibited sunitinib-induced cardiomyocyte autophagy and apoptosis, and the HMGB1-specific inhibitor glycyrrhizic acid (GA) significantly mitigated sunitinib-induced autophagy, cardiomyocyte death and cardiotoxicity. Our study reveals a novel target protein of autophagic degradation in the regulation of cardiomyocyte death and highlights the pharmacological inhibitor of HMGB1 as an attractive approach for improving the safety of sunitinib-based cancer therapy. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
5. PLK1 (polo like kinase 1)-dependent autophagy facilitates gefitinib-induced hepatotoxicity by degrading COX6A1 (cytochrome c oxidase subunit 6A1).
- Author
-
Luo, Peihua, Yan, Hao, Du, Jiangxia, Chen, Xueqin, Shao, Jinjin, Zhang, Ying, Xu, Zhifei, Jin, Ying, Lin, Nengming, Yang, Bo, and He, Qiaojun
- Subjects
CYTOCHROME oxidase ,TUBULINS ,EPIDERMAL growth factor receptors ,AUTOPHAGY ,PHYSIOLOGIC salines ,ASPARTATE aminotransferase ,NON-small-cell lung carcinoma - Abstract
Liver dysfunction is an outstanding dose-limiting toxicity of gefitinib, an EGFR (epidermal growth factor receptor)-tyrosine kinase inhibitor (TKI), in the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC). We aimed to elucidate the mechanisms underlying gefitinib-induced hepatotoxicity, and provide potentially effective intervention strategy. We discovered that gefitinib could sequentially activate macroautophagy/autophagy and apoptosis in hepatocytes. The inhibition of autophagy alleviated gefitinib-induced apoptosis, whereas the suppression of apoptosis failed to lessen gefitinib-induced autophagy. Moreover, liver-specific Atg7
+/− heterozygous mice showed less severe liver injury than vehicle, suggesting that autophagy is involved in the gefitinib-promoted hepatotoxicity. Mechanistically, gefitinib selectively degrades the important anti-apoptosis factor COX6A1 (cytochrome c oxidase subunit 6A1) in the autophagy-lysosome pathway. The gefitinib-induced COX6A1 reduction impairs mitochondrial respiratory chain complex IV (RCC IV) function, which in turn activates apoptosis, hence causing liver injury. Notably, this autophagy-promoted apoptosis is dependent on PLK1 (polo like kinase 1). Both AAV8-mediated Plk1 knockdown and PLK1 inhibitor BI-2536 could mitigate the gefitinib-induced hepatotoxicity in vivo by abrogating the autophagic degradation of the COX6A1 protein. In addition, PLK1 inhibition could not compromise the anti-cancer activity of gefitinib. In conclusion, our findings reveal the gefitinib-hepatotoxicity pathway, wherein autophagy promotes apoptosis through COX6A1 degradation, and highlight pharmacological inhibition of PLK1 as an attractive therapeutic approach toward improving the safety of gefitinib-based cancer therapy. Abbreviations: 3-MA: 3-methyladenine; AAV8: adeno-associated virus serotype 8; ATG5: autophagy related 5; ATG7: autophagy related 7; B2M: beta-2-microglobulin; CCCP: carbonyl cyanide m-chlorophenylhydrazone; CHX: cycloheximide; COX6A1: cytochrome c oxidase subunit 6A1; c-PARP: cleaved poly(ADP-ribose) polymerase; CQ: chloroquine; GOT1/AST: glutamic-oxaloacetic transaminase 1, soluble; GPT/ALT: glutamic pyruvic transaminase, soluble; HBSS: Hanks´ balanced salt solution; H&E: hematoxylin and eosin; MAP1LC3/LC3: microtubule associated proteins 1 light chain 3; PLK1: polo like kinase 1; RCC IV: respiratory chain complex IV; ROS: reactive oxygen species; TUBB8: tubulin beta 8 class VIII [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
6. ROS-dependent DNA damage contributes to crizotinib-induced hepatotoxicity via the apoptotic pathway.
- Author
-
Yan, Hao, Du, Jiangxia, Chen, Xueqin, Yang, Bo, He, Qiaojun, Yang, Xiaochun, and Luo, Peihua
- Subjects
- *
DNA damage , *ANAPLASTIC lymphoma kinase , *HEPATOTOXICOLOGY , *PROTEIN-tyrosine kinases , *MITOCHONDRIAL membranes , *MEMBRANE potential - Abstract
Crizotinib is an oral small-molecule tyrosine kinase inhibitor targeting anaplastic lymphoma kinase (ALK), ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) and MET proto-oncogene, receptor tyrosine kinase (MET). Unfortunately, hepatotoxicity is a serious limitation in its clinical application, and the reason remains largely unknown. In this study, we tested the effect of crizotinib in human hepatocyte cell line HL-7702 and human primary hepatocytes, and the results showed that crizotinib treatment caused hepatocyte damage, suggesting that crizotinib induced liver injury by causing hepatocyte death, consistent with the clinical cases. Mechanistically, crizotinib induced hepatocyte death via the apoptotic pathway, and cleaved PARP (c-PARP) was observed as a signaling protein. Moreover, mitochondrial membrane potential (MMP) decrease contributed to crizotinib-induced hepatocyte apoptosis accompanied by hepatocyte DNA damage and reactive oxygen species (ROS) generation. Importantly, crizotinib induced hepatocyte apoptosis independent of its targets, ALK, ROS1 and MET. In conclusion, our data showed that crizotinib induced liver injury through hepatocyte death via the apoptotic pathway which was independent of ALK, ROS1 and MET. And we also found that MMP decrease, DNA damage and ROS generation were involved in the process. Unlabelled Image • Crizotinib causes hepatocellular damage via the apoptotic pathway. • Mitochondrial membrane potential (MMP) decrease is involved in crizotinib-induced apoptosis. • Crizotinib induces reactive oxygen species (ROS) generation and DNA damage. • Crizotinib-induced hepatotoxicity is independent of ALK, ROS1 and MET. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
7. IKULDAS: An Improved kNN-Based UHF RFID Indoor Localization Algorithm for Directional Radiation Scenario.
- Author
-
Shi, Weiguang, Du, Jiangxia, Cao, Xiaowei, Yu, Yang, Cao, Yu, Yan, Shuxia, and Ni, Chunya
- Subjects
- *
K-nearest neighbor classification , *UHF detectors , *RADIO frequency identification systems , *UHF antennas , *PROBLEM solving - Abstract
Ultra high frequency radio frequency identification (UHF RFID)-based indoor localization technology has been a competitive candidate for context-awareness services. Previous works mainly utilize a simplified Friis transmission equation for simulating/rectifying received signal strength indicator (RSSI) values, in which the directional radiation of tag antenna and reader antenna was not fully considered, leading to unfavorable performance degradation. Moreover, a k-nearest neighbor (kNN) algorithm is widely used in existing systems, whereas the selection of an appropriate k value remains a critical issue. To solve such problems, this paper presents an improved kNN-based indoor localization algorithm for a directional radiation scenario, IKULDAS. Based on the gain features of dipole antenna and patch antenna, a novel RSSI estimation model is first established. By introducing the inclination angle and rotation angle to characterize the antenna postures, the gains of tag antenna and reader antenna referring to direct path and reflection paths are re-expressed. Then, three strategies are proposed and embedded into typical kNN for improving the localization performance. In IKULDAS, the optimal single fixed rotation angle is introduced for filtering a superior measurement and an NJW-based algorithm is advised for extracting nearest-neighbor reference tags. Furthermore, a dynamic mapping mechanism is proposed to accelerate the tracking process. Simulation results show that IKULDAS achieves a higher positioning accuracy and lower time consumption compared to other typical algorithms. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
8. Bisdemethoxycurcumin protects against renal fibrosis via activation of fibroblast apoptosis.
- Author
-
Jin, Fuquan, Jin, Ying, Du, Jiangxia, Jiang, Liyu, Zhang, Ying, Zhao, Ziying, Yang, Bo, Luo, Peihua, and He, Qiaojun
- Subjects
- *
RENAL fibrosis , *FIBROBLASTS , *APOPTOSIS , *KIDNEY diseases , *NATURAL products - Abstract
Abstract Renal fibrosis is the common final outcome of nearly all progressive chronic kidney diseases (CKD) that eventually develop into end-stage renal failure, which threatens the lives of patients. Currently, there are no effective drugs for the treatment of renal fibrosis. However, studies have shown that certain plant natural products have a fibrosis-alleviating effect. Thus, we have screened a large number of natural products for their ability to protect against renal fibrosis and found that bisdemethoxycurcumin has a good therapeutic effect in renal fibrosis according to the data obtained in a mouse model of unilateral ureteral obstruction (UUO). The results indicate that bisdemethoxycurcumin can efficiently attenuate renal fibrosis induced by UUO. Additional studies of the bisdemethoxycurcumin mechanism of action in the treatment of renal fibrosis demonstrated that the therapeutic effect of bisdemethoxycurcumin is mediated by the specific induction of fibroblast apoptosis at a concentration of 20 μM. bisdemethoxycurcumin can efficiently protect against renal fibrosis both in vitro and in vivo. This discovery will provide new ideas for renal fibrosis treatment in clinics and a new direction for the development of effective drug therapy of renal fibrosis. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
9. Macrophage-secreted TSLP and MMP9 promote bleomycin-induced pulmonary fibrosis.
- Author
-
Li, Guanqun, Jin, Fuquan, Du, Jiangxia, He, Qiaojun, Yang, Bo, and Luo, Peihua
- Subjects
- *
BLEOMYCIN , *PULMONARY fibrosis , *MATRIX metalloproteinases , *MESENCHYMAL stem cells , *CELL migration , *MACROPHAGES - Abstract
Abstract Idiopathic pulmonary fibrosis is a pathological result of dysfunctional repair response to tissue injury, leading to chronically impaired gas exchange and death. Macrophages are believed to be critical in this disease pathogenesis; However, the exact mechanisms remain enigmatic. Here, we demonstrated that macrophages might contribute to pulmonary fibrosis at the early stage because the aggregation of macrophages appeared earlier than epithelial-mesenchymal transition and fibrosis in mouse and rat experimental models of pulmonary fibrosis. It has been found that macrophages could promote epithelial-mesenchymal transition of alveolar epithelial cells and fibroblast migration in co-culture models between macrophages and alveolar epithelial cells/fibroblasts. Importantly, we used protein micro array to analyze the cytokines that were altered after bleomycin treatment. Only thymic stromal lymphopoietin and matrix metalloproteinase 9 were significantly increased. We further confirmed that TSLP participated in the macrophage-induced epithelial-mesenchymal transition of alveolar epithelial cells using a TSLP recombinant protein. MMP9 was also involved in macrophage-induced fibroblast migration, which can be reversed by an inhibitor of MMP9. Collectively, these findings explained the underlying mechanisms of macrophage-promoted pulmonary fibrosis. Highlights • Macrophages contribute to bleomycin-induced pulmonary fibrosis • TSLP and MMP9 may be pivotal cytokines secreted by macrophages • TSLP may induce epithelial-mesenchymal transition of alveolar epithelial cells • MMP9 is involved in macrophage-induced fibroblast migration [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
10. Cutaneous toxicity of FDA-approved small-molecule kinase inhibitors.
- Author
-
Du J, Yan H, Xu Z, Yang B, He Q, Wang X, and Luo P
- Subjects
- Drug Approval, Humans, United States, United States Food and Drug Administration, Protein Kinase Inhibitors adverse effects, Skin Diseases chemically induced
- Abstract
Introduction: By 1 January 2021, the FDA has approved a total of 62 small-molecule kinase inhibitors (SMKIs). The increasing clinical use of small-molecule kinase inhibitors has led to some side effects, the most common of which is cutaneous toxicity, as reflected by approximately 90% (57 of 62) of the FDA-approved SMKIs have reported treatment-related cutaneous toxicities. Since these cutaneous toxicities may have a crucial influence on the emotional, physical and psychosocial health of the patients, it is of great importance for doctors, patients, oncologists and interrelated researchers to be aware of the cutaneous side effects of these drugs in order to make the diagnosis accurate and the treatment appropriate., Areas Covered: This review aims to summarize the potential cutaneous toxicities and the frequency of occurrence of FDA-approved 62 SMKIs, and provide a succinct overview of the potential mechanisms of certain cutaneous toxicities. The literature review was performed based on PubMed database and FDA official website., Expert Opinion: It is significant to determine the risk factors for SMKI-induced cutaneous toxicity. The mechanisms underlying SMKI-induced cutaneous toxicities remain unclear at present. Future research should focus on the mechanisms of SMKI-induced cutaneous toxicities to find out mechanistically driven therapies.
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.